MedTrace Logo

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

NCT00047762 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.

Conditions

Interventions

DRUG

Erlotinib (aka Tarceva or OSI-774)

DRUG

Bevacizumab (aka Avastin or Rhu MAb VEGF)

Sponsors & Collaborators

  • Genentech, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00047762 on ClinicalTrials.gov